<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944645</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-059</org_study_id>
    <secondary_id>MK0524A-059</secondary_id>
    <secondary_id>2009_613</secondary_id>
    <nct_id>NCT00944645</nct_id>
  </id_info>
  <brief_title>MK0524A Bioequivalence Study (0524A-059)</brief_title>
  <official_title>An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg
      Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Nicotinuric Acid</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
    <description>Measure of rate of absorption of ER niacin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Urinary Excretion of Niacin and Its Metabolites</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>Measure of extent of absorption of ER niacin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC 0-infinity) of Laropiprant</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Measure of extent of absorption of laropiprant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Laropiprant</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Measure of rate of absorption of laropiprant</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MK0524A Source 1 (Phase III manufacturing site)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MK0524A Source 2 (commercial manufacturing site)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin (+) laropiprant (Source 1)</intervention_name>
    <description>Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: niacin (+) laropiprant (Source 2)</intervention_name>
    <description>Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is in good health

          -  Subject is willing to follow all study guidelines

        Exclusion Criteria:

          -  Subject has or has a history of any disease or condition that might confound the
             results of the study or make participation unsafe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <results_first_submitted>October 20, 2009</results_first_submitted>
  <results_first_submitted_qc>October 20, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2009</results_first_posted>
  <last_update_submitted>May 25, 2015</last_update_submitted>
  <last_update_submitted_qc>May 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK0524A Phase III Tablet Then MK0524A New Site Tablet</title>
          <description>MK0524A Phase III tablet: MK0524A (1000 mg ER Niacin/20 mg MK0524) Phase III tablet (Source 1)/MK0524A New Site tablet: MK0524A (1000 mg ER Niacin/20 mg MK0524) tablet from new manufacturing site (Source 2)</description>
        </group>
        <group group_id="P2">
          <title>MK0524A New Site Tablet Then MK0524A Phase III Tablet</title>
          <description>MK0524A New Site tablet: MK0524A (1000 mg ER Niacin/20 mg MK0524) tablet from new manufacturing site (Source 2)/ MK0524A Phase III tablet: MK0524A (1000 mg ER Niacin/20 mg MK0524) Phase III tablet (Source 1)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Includes all participants from Both treatment groups; MK0524A Phase III tablet and MK0524A New Site tablet</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="1" lower_limit="18" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.6" lower_limit="140" upper_limit="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.6" lower_limit="48.4" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Nicotinuric Acid</title>
        <description>Measure of rate of absorption of ER niacin</description>
        <time_frame>Predose and up to 24 hours postdose</time_frame>
        <population>The Hodges-Lehmann estimator was used to analyze nicotinuric acid Cmax and uses only subjects with data available on both treatment periods. 188 subjects were randomized,17 subjects discontinued, 26 subjects were inadvertently overdosed with 5 tablets of MK0524A 1000 mg/20 mg, reducing the available subject population for analysis to 145.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0524A New Site Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) tablet from new manufacturing site (Source 2)</description>
          </group>
          <group group_id="O2">
            <title>MK0524A Phase III Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) Phase III tablet (Source 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Nicotinuric Acid</title>
          <description>Measure of rate of absorption of ER niacin</description>
          <population>The Hodges-Lehmann estimator was used to analyze nicotinuric acid Cmax and uses only subjects with data available on both treatment periods. 188 subjects were randomized,17 subjects discontinued, 26 subjects were inadvertently overdosed with 5 tablets of MK0524A 1000 mg/20 mg, reducing the available subject population for analysis to 145.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1190" lower_limit="956" upper_limit="1610"/>
                    <measurement group_id="O2" value="1260" lower_limit="948" upper_limit="1660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) tablet from new manufacturing site (Source 2)
MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) Phase III tablet (Source 1)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary research hypothesis I: The Cmax of nicotinuric acid (NUA) following the administration of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) tablets from 2 manufacturing sites is similar (i.e., the true GMR of NUA Cmax is contained within the bioequivalence interval (0.80, 1.25)).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Urinary Excretion of Niacin and Its Metabolites</title>
        <description>Measure of extent of absorption of ER niacin</description>
        <time_frame>Predose and up to 96 hours postdose</time_frame>
        <population>A linear mixed effect model was used to analyze total amount of urinary excretion of niacin and its metabolite and uses data available from at least one treatment period. 157 subjects had data from the treatment of MK0524A New Site Tablet, and 161 subjects had data from the treatment of MK0524A Phase III Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>MK0524A New Site Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) tablet from new manufacturing site (Source 2)</description>
          </group>
          <group group_id="O2">
            <title>MK0524A Phase III Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) Phase III tablet (Source 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Urinary Excretion of Niacin and Its Metabolites</title>
          <description>Measure of extent of absorption of ER niacin</description>
          <population>A linear mixed effect model was used to analyze total amount of urinary excretion of niacin and its metabolite and uses data available from at least one treatment period. 157 subjects had data from the treatment of MK0524A New Site Tablet, and 161 subjects had data from the treatment of MK0524A Phase III Tablet</population>
          <units>micro mole</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5280" spread="1894"/>
                    <measurement group_id="O2" value="5470" spread="1330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) tablet from new manufacturing site (Source 2)
MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) Phase III tablet (Source 1)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary research hypothesis II: The total urinary excretion of niacin and niacin metabolites following the administration of MK0524 (ER niacin 1000 mg/ laropiprant 20 mg) tablets from 2 manufacturing sites is similar (i.e., the true GMR of total urinary excretion of niacin and its metabolites is contained within the bioequivalence interval (0.80, 1.25)).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under Curve (AUC 0-infinity) of Laropiprant</title>
        <description>Measure of extent of absorption of laropiprant</description>
        <time_frame>Predose and up to 48 hours postdose</time_frame>
        <population>A linear mixed effect model was used to analyze laropiprant AUC0-infinity and uses data available from at least one treatment period. 166 subjects had data from the treatment of MK0524A New Site Tablet, and 167 subjects had data from the treatment of MK0524A Phase III Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>MK0524A New Site Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) tablet from new manufacturing site (Source 2)</description>
          </group>
          <group group_id="O2">
            <title>MK0524A Phase III Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) Phase III tablet (Source 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve (AUC 0-infinity) of Laropiprant</title>
          <description>Measure of extent of absorption of laropiprant</description>
          <population>A linear mixed effect model was used to analyze laropiprant AUC0-infinity and uses data available from at least one treatment period. 166 subjects had data from the treatment of MK0524A New Site Tablet, and 167 subjects had data from the treatment of MK0524A Phase III Tablet</population>
          <units>Micro Molar times Hour</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="3.01"/>
                    <measurement group_id="O2" value="6.37" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group B: MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) tablet from new manufacturing site (Source 2)
Group A: MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) Phase III tablet (Source 1)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary research hypothesis III: The AUC0-infinity of laropiprant following the administration of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) tablets from 2 manufacturing sites is similar (i.e., the true GMR of MK0524 AUC0-âˆž is contained within the bioequivalence interval (0.80, 1.25)).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Laropiprant</title>
        <description>Measure of rate of absorption of laropiprant</description>
        <time_frame>Predose and up to 48 hours postdose</time_frame>
        <population>A linear mixed effect model was used to analyze laropiprant Cmax and uses data available from at least one treatment period. 166 subjects had data from the treatment of MK0524A New Site Tablet, and 167 subjects had data from the treatment of MK0524A Phase III Tablet.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0524A New Site Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) tablet from new manufacturing site (Source 2)</description>
          </group>
          <group group_id="O2">
            <title>MK0524A Phase III Tablet</title>
            <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) Phase III tablet (Source 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Laropiprant</title>
          <description>Measure of rate of absorption of laropiprant</description>
          <population>A linear mixed effect model was used to analyze laropiprant Cmax and uses data available from at least one treatment period. 166 subjects had data from the treatment of MK0524A New Site Tablet, and 167 subjects had data from the treatment of MK0524A Phase III Tablet.</population>
          <units>micro Molar</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988" spread="0.563"/>
                    <measurement group_id="O2" value="0.975" spread="0.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) tablet from new manufacturing site (Source 2)
MK0524A (1000 mg ER Niacin/20 mg MK-laropiprant) Phase III tablet (Source 1)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary research hypothesis IV: The Cmax of laropiprant following the administration of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) tablets from 2 manufacturing sites is similar (i.e., the true GMR of MK0524 Cmax is contained within the bioequivalence interval (0.80, 1.25)).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MK0524A Phase III Tablet</title>
          <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) Phase III tablet (Source 1)</description>
        </group>
        <group group_id="E2">
          <title>MK0524A New Site Tablet</title>
          <description>MK0524A (1000 mg ER Niacin/20 mg laropiprant) tablet from new manufacturing site (Source 2)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Defaecation Urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Epigastric Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Blood Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Helicobacter Pylori Identification Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Occult Blood Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pruritus Generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

